The Neuromuscular Center Schleswig-Holstein is a network of centers lead by the University Hospital Schleswig-Holstein in Lübeck and Kiel and the Precision Neurology of neuromuscular diseases at the University of Luebeck.
We offer comprehensive care for patients with neuromuscular diseases, muscle diseases and motor neuron diseases. The entire range of neurological, neurophysiological, neuropathological and human genetic examination techniques are available for outpatient, day clinic and inpatient diagnostics. The department for Neurology has its own intensive care unit for crisis intervention and the application of nutritional support, and in cooperation with the departments for pulmonology for adaptation and testing of home respiration, the departments of cardiology, rheumatology, childrens hospital, genetics and neurogenetics.
We provide advice to patients and their relatives, as well as to physicians in private practice, on questions of diagnostics and therapy, the provision of aids and remedies, nutrition and nutritional aids, physiotherapeutic, ergotherapeutic and logopedic care, home respiration, and, if required, on questions of palliative medical care and treatment in the advanced stages of severe illnesses. We are running the north-western ALS registry ALSMOND and offer a range of observational and basic research trials. Our center conducts clinical trials from phase I-IV and cooperated on a national and international level with researcher world wide.
| Neuromuscular Center Schleswig-Holstein | |
|---|---|
| Foundation year | 2021 |
| Director | Prof. Dr Julian Grosskreutz |
| Principal investigator | Prof. Dr Julian Grosskreutz |
| Contact information | |
|---|---|
| Address | Universitätsklinikum Schleswig-Holstein (UKSH) |
| Contact | Prof. Dr Julian Grosskreutz |
| Phone | +49 451-500-43450 |
| pnl@neuro.uni-luebeck.de | |
| Website | Visit the website |
Publications
- Gaur N, Steinbach R, Plaas M, Witte OW, Brill MS, Grosskreutz J. Chitinase dysregulation predicts disease aggressiveness in ALS: Insights from the D50 progression model. J Neurol Neurosurg Psychiatry. 2023 Jul;94(7):585-588. doi:10.1136/jnnp-2022-330318. Epub 2023 Apr 19. PMID: 37076292.
- Ebersbach T, Roediger A, Steinbach R, Appelfeller M, Tuemmler A, Stubendorff B, Axer H, Witte OW, Grosskreutz J. Motor unit number index (MUNIX) loss of 50% occurs in half the time of 50% functional loss according to the D50 disease progression model of ALS. Sci Rep. 2023 Mar 9;13(1):3981. doi: 10.1038/s41598-023-30871-x. PMID: 36894607; PMCID: PMC9998642.
-
Maier A, .., Großkreutz J, … Ludolph A, Meyer T; MND-NET consensus group. ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale. Neurol Res Pract. 2022 Dec 15;4(1):60. doi: 10.1186/s42466-022-00224-6.
- Prell T, .. , Grosskreutz J, Teschner U. Data on medication adherence in adults with neurological disorders: The NeuroGerAd study. Sci Data. 2022 Nov 30;9(1):734. doi: 10.1038/s41597-022-01847-9.
- Metzner K, Darawsha O, .. , Grosskreutz J, Brill MS. Age-dependent increase of cytoskeletal components in sensory axons in human skin. Front Cell Dev Biol. 2022 Nov 1;10:965382. doi: 10.3389/fcell.2022.965382.
Grosskreutz J – Search Results – PubMed (nih.gov)
https://scholar.google.de/citations?user=A2md6kkAAAAJ&hl=de
Restricted information
| Serving population | |
|---|---|
| Serving population | 6 mio |
| Patient resources | |
|---|---|
| Population based register | Yes |
| Clinic based register | Yes |
| Geographically matched controls | Yes |
| Number of skin samples | 30 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA bank | 400 | 50 | 10 |
| Serum bank | 600 | 100 | 10 |
| RNA bank | 110 | 30 | 10 |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | Yes |
| Transcriptomics | Yes |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| Courage | Phase 3 | 21 |
| Momenta (Janssen) | Phase 3 | 0 |
| HIMALAYA (Sanofi-Aventis) | Phase 2 | 20 |
| PTC-Cardinals (PTC Therapeutics) | Phase 2 | 0 |
| 0ANQUR (QurAlis Cooperation) | Phase Ib | -28 |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| ID-ALS (Charité-Studie, cooperation with Ambulanzpartner) | Registry study | 74 |
| NF-L (Charité-Studie, cooperation with Ambulanzpartner) | Registry study | 76 |
| ALSMOND (Neuromuskulaeres Zentrum Schleswig-Holstein) | Registry study | 90 |
| Tofersen (Biogen) | Compassionate use | 2 |